Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

AstraZeneca, Daiichi Sankyo's Enhertu wins NICE approval for HER2-low breast cancer NHS access
Antibody-drug conjugate, breast cancer, reimbursement, competitive - Read more

Japan's MHLW approves GSK's Shingrix (recombinant zoster vaccine) prefilled syringe for shingles prevention
Vaccine, infectious disease, recombinant vaccine, shingles, varicella-zoster virus, adjuvant system - Read more

Bayer's Kerendia (finerenone) wins third FDA approval for chronic kidney disease associated with type 1 diabetes
Small molecule, metabolic, cardiovascular, mineralocorticoid receptor antagonist, chronic kidney disease, type 1 diabetes - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Cellares, GenomeFrontier Therapeutics partner to evaluate Cell Shuttle platform for virus-free CAR-T manufacturing
Research collaboration, cell therapy, manufacturing, oncology, automation - Read more

Novo, Orbis Medicines partner on oral macrocycle cardiometabolic therapies, up to $1.4B in milestones
Co-development, cardiometabolic, small molecule, drug discovery, milestone payments, equity investment - Read more

SK Biopharmaceuticals, 1ST Biotherapeutics ink $314.8M deal for Parkinson's LRRK2 inhibitor 1ST-104
Licensing deal, neurological, small molecule, milestone payments, equity investment - Read more

EpilepsyGTx, Viralgen partner to scale AAV manufacturing for EPY201 ahead of first-in-human trials
Manufacturing agreement, gene therapy, neurological, AAV manufacturing - Read more

Roche, Dualitas Therapeutics partner on bispecific antibody platform for immunology, $36.5M upfront, up to $1B
Licensing deal, bispecific antibody, autoimmune, drug discovery, milestone payments, royalties - Read more

Novo, Anthropic collaborate to accelerate drug discovery and development using AI models
Research collaboration, AI/ML, drug discovery, R&D - Read more

Standigm, Protai launch joint R&D program to design selective molecular glue degraders using AI and structural proteomics
Research collaboration, AI/ML, small molecule, drug discovery, proteomics - Read more

Roche's Lunsumio (mosunetuzumab) meets Ph3 primary endpoint, improving progression-free survival in relapsed or refractory follicular lymphoma
Antibody, cancer, bispecific antibody, follicular lymphoma, CD20xCD3, combination therapy - Read more

Reckitt allots $600M to upgrade U.S. operations, expanding manufacturing and R&D capabilities
OTC drugs, consumer health, operational, major transaction - Read more

North Immunology goes public via reverse merger with Aethlon Medical, raising $180M for eczema drug NOR-101
Bispecific antibody, dermatology, major transaction, financial - Read more

Lisata Therapeutics merges with Marea Therapeutics in reverse merger, raising $225M after failed Kuva Labs acquisition
Small molecule, cardiovascular, strategic, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Longeveron's (laromestrocel) stem cell therapy fails Ph2b trial in hypoplastic left heart syndrome
Cell therapy, cardiovascular, stem cell therapy, hypoplastic left heart syndrome, congenital heart disease - Read more

Boehringer Ingelheim terminates Ph3 EASi-KIDNEY trial of vicadrostat (BI 690517) in chronic kidney disease
Small molecule, cardiovascular, aldosterone synthase inhibitor, chronic kidney disease, SGLT2 inhibitor, combination therapy - Read more

Bristol Myers Squibb, Ono Pharmaceutical face expanded patent infringement claims from Amgen over Opdivo/Opdualag
Antibody, oncology, patent litigation, competitive, royalties - Read more

FDA issues warning letter to Bausch & Lomb over contamination failures, citing lack of remediation commitment
Sterile manufacturing, ophthalmology, operational, regulatory, quality management - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here